natgillin/translations-raw huggingface dataset:
Til patienter (børn), der ikke er i stand til at synke kapslerne, kan indholdet opløses i et glas almindeligt vand eller æblejuice. 
For patients (children) unable to swallow the capsules, their content may be diluted in a glass of either still water or apple juice.
Imatinib Teva er indiceret til: 
Imatinib Teva is indicated for
30 hårde kapsler 30x1 hårde kapsler 90 hårde kapsler 90x1 hårde kapsler 
30 hard capsules 30x1 hard capsules 90 hard capsules 90x1 hard capsules
CML i accelereret fase og blastkrise og Ph+ALL (startdosis 600 mg) 
Accelerated phase CML and blast crisis and Ph+ ALL (starting dose 600 mg)
Disse patienter fik Imatinib Teva i en periode varierende mellem 24 dage og 60 måneder (median 47 måneder). 
These patients received imatinib for a median of 47 months (range 24 days - 60 months).
En fertilitetsundersøgelse med hanrotter doseret i 70 dage før parring, sås nedsat testikel- og epididymisvægt samt reduceret antal bevægelige sædceller ved 60 mg/kg, ca. svarende til den maksimale kliniske dosis på 800 mg/dag, baseret på legemsoverfladeareal. 
In a study of fertility, in male rats dosed for 70 days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
Doser på 400 mg og 600 mg bør administreres 1 gang daglig, mens daglige doser på 800 mg bør administreres som 400 mg 2 gange daglig, én dosis om morgenen og én dosis om aftenen. 
Doses of 400 mg or 600 mg should be administered once daily, whereas a daily dose of 800 mg should be administered as 400 mg twice a day, in the morning and in the evening.
Frekvensen for fuldstændig hæmatologisk respons, cytogenetisk respons og fuldstændig cytogenetisk respons for førstevalgsbehandling blev estimeret ved brug af Kaplan-Meier-metoden, hvor patienter, der ikke responderede, blev sorteret fra ved datoen for sidste undersøgelse. 
Rates of complete haematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which non-responses were censored at the date of last examination.
(24 timer), dag 1, 15; 6MP 25 mg/m2 oral, dag 1-20 
(24 h), days 1, 15; 6-MP 25 mg/m2 oral, days 1-20
- hvis du er allergisk over for imatinib eller et af de øvrige indholdsstoffer Imatinib Teva (angivet i punkt 6). 
Do not take Imatinib Teva - if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6).
(2 timer, q 12 timer), dag 2-3 (total af 8 omgange) 
(2 h, q 12 h), days 2-3 (total of 8
- Du må ikke amme, mens du er i behandling med Imatinib Teva. 
- Do not breast-feed during the treatment with Imatinib Teva.
Der er kun begrænset erfaring med Imatinib Teva hos patienter med MDS/MPD forbundet med PDGFR-omlejring (se pkt 5.1). 
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Færre end 1% af CML-patienterne fik seponeret behandlingen permanent på grund af abnormaliteter i levertal. 
Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1% of CML patients.
Akut lymfoblast leukæmi er en form af leukæmi, hvor visse abnorme hvide blodlegemer (kaldet lymfoblaster) vokser ukontrolleret. 
Acute lymphoblastic leukaemia is a form of leukaemia in which certain abnormal white cells (named lymphoblasts) start growing out of control.
Palmoplantar erytrodysæstesi syndrom*, lichenoid keratosis*, lichen planus*, toksisk epidermal nekrolyse*, medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS)*, pseudoporfyri* 
Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)*, pseudoporphyria* Musculoskeletal and connective tissue disorders Very common
Der er begrænset erfaring hos børn og Ph-positiv ALL og meget begrænset erfaring med børn med MDS/MPD, DFSP og HEL/CEL. 
There is limited experience in children with Ph-positive ALL and very limited experience in children with MDS/MPD, DFSP and HES/CEL.
• Have kvalme med tab af appetitten, mørk urin, gul hud eller øjne (tegn på leverproblemer). 
• Feeling sick (nausea), with loss of appetite, dark-coloured urine, yellow skin or eyes (signs of liver problems).
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller 4. grads neutropeni (ANC <1,0 x 109/l) og trombocytopeni (trombocyttal <50 x 109/l) var 4-6 gange højere ved blastkrise og accelereret fase (59-64% og 44-63% for henholdsvis neutropeni og trombopeni) end ved sammenligning med nydiagnosticerede patienter med kronisk fase CML (16,7% neutropeni og 8,9% trombocytopeni). 
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 109/l) and thrombocytopenias (platelet count < 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
NAME OF THE MARKETING AUTHORISATION HOLDER 
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
15 mg intrathecal, dag 1; methylprednisolon 40 mg intrathecal, dag 1 
MTX 15 mg intrathecal, day 1; Methylprednisolone 40 mg intrathecal, day 1
- hvis du får blå mærker, blødninger, feber, træthed og oplever forvirring, mens du tager Imatinib Teva, skal du kontakte din læge. 
- if you experience bruising, bleeding, fever, fatigue and confusion when taking Imatinib Teva,
Total bilirubin: > 3-10 ULN AST: alt 
Total bilirubin: > 3-10 ULN
Imatinib metaboliseres primært i leveren. 
Imatinib is mainly metabolised through the liver.
Accelereret fase defineres som tilstedeværelse af én eller flere af følgende: blaster ≥15%, men <30% i blod eller knoglemarv, blaster plus promyelocytter ≥30% i blod eller knoglemarv (hvilket giver <30% blaster), perifere blodbasofiltal ≥20%, trombocyttal <100 x 109/l uafhængigt af behandlingen. 
Accelerated phase is defined by the presence of any of the following: blasts ≥ 15% but < 30% in blood or bone marrow, blasts plus promyelocytes ≥ 30% in blood or bone marrow (providing < 30% blasts), peripheral blood basophils ≥ 20%, platelets < 100 x 109/l unrelated to therapy.
VCR 1,3 g/m2 i.v., dag 1; prednisolon 60 mg/m2 oral, dag 1-5 
VCR 1.3 g/m2 i.v., day 1; Prednisolone 60 mg/m2 oral, days 1-5
- Philadelphia kromosom positiv akut lymfoblast leukæmi (Ph-positiv ALL). 
- Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL).
Hvis dette gælder for dig, skal du fortælle din læge det, før du tager Imatinib Teva. 
If this applies to you, tell your doctor without taking Imatinib Teva.
Genoptag behandling med Imatinib Teva 600 mg. 
Resume treatment with imatinib at 600 mg.
Dosisøgning fra 340 mg/m2 daglig til 570 mg/m2 daglig (uden at overstige total dosis på 800 mg) kan overvejes hos børn ved fravær af alvorlige bivirkninger og svær ikke-leukæmirelateret neutropeni eller trombocytopeni ved følgende omstændigheder: sygdomsprogression (på ethvert tidspunkt); hvis der ikke er opnået tilfredsstillende hæmatologisk respons efter mindst 3 måneders behandling; hvis der ikke er opnået cytogenetisk respons efter 12 måneders behandling; eller ved tab af tidligere opnået hæmatologisk og/eller cytogenetisk respons. 
Dose increases from 340 mg/m2 daily to 570 mg/m2 daily (not to exceed the total dose of 800 mg) may be considered in children in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
Brug af anden medicin sammen med Imatinib Teva 
Other medicines and Imatinib Teva
Kvalme, diarré, opkast, dyspepsi, abdominalsmerter 6 
Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain6
• Muskelkramper eller led-, muskel- eller knoglesmerter mens du er i behandling med Imatinib 
• Muscle cramps or joint, muscle or bone pain, during treatment with Imatinib Teva or after you have stopped taking Imatinib Teva.
Hvis noget af det ovenstående gælder for dig, skal du fortælle din læge det, før du tager Imatinib Teva. 
If any of these apply to you, tell your doctor before taking Imatinib Teva
Patienter, der ikke er i stand til at synke de filmovertrukne tabletter, kan dispergere tabletterne i et glas med almindeligt vand eller æblejuice. 
For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of still water or apple juice.
• Udslæt, rød hud med små blærer på læber, øjne, hud eller mund, afskallet hud, feber, hævede røde eller lilla hudområder, kløe, brændende fornemmelse, pustuløst udslæt (tegn på hudproblemer). 
• Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
Tabel 3 Respons hos voksne CML-patienter 
Table 3 Response in adult CML study
Dosisøgninger fra 400 mg til 600 mg eller 800 mg til patienter med CML i kronisk fase, eller fra 600 mg til maksimalt 800 mg (givet som 400 mg 2 gange daglig) til patienter i accelereret fase eller i blastkrise kan, hvis der ikke opstår svære bivirkninger og svær ikke-leukæmirelateret neutropeni eller trombocytopeni, overvejes i følgende tilfælde: Sygdomsprogression (til enhver tid), udeblivende tilfredsstillende hæmatologisk respons efter mindst 3 måneders behandling, udeblivende opnåelse af cytogenetisk respons efter 12 måneders behandling, samt hvis tidligere hæmatologisk og/eller cytogenetisk respons ikke genopnås. 
Dose increases from 400 mg to 600 mg or 800 mg in patients with chronic phase disease, or from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
• Voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. 
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
Recidiverendet/refraktær Ph+ ALL 
Relapsed/refractory Ph+ ALL
Nydiagnostiseret Ph+ ALL 
Newly diagnosed Ph+ ALL
Hvis du ikke kan synke tabletterne, kan du opløse dem i et glas almindeligt vand eller æblejuice: 
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice:
Imatinib hæmmer også receptortyrosinkinaserne for trombocytafledte vækstfaktorer (PDGF), PDGFR, og hæmmer PDGF-medierede cellulære signaler. 
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events.
Den primære effektvariable var graden af hæmatologisk hovedrespons, rapporteret enten som fuldstændigt hæmatologisk respons, intet tegn på leukæmi, eller remission til CML i kronisk fase, med anvendelse af samme kriterier som i undersøgelsen med patienter i accelereret fase. 
The primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia, or return to chronic phase CML using the same criteria as for the study in accelerated phase.
- Hvis du glemmer at tage en dosis, så tag den, så snart du kommer i tanker om det. 
If you forget to take Imatinib Teva - If you forget a dose, take it as soon as you remember.
Bliv ved med at tage Imatinib Teva hver dag, så længe som lægen har foreskrevet det. 
How long to take Imatinib Teva Keep taking Imatinib Teva every day for as long as your doctor tells you.
20x1 hårde kapsler 60 hårde kapsler 60x1 hårde kapsler 120 hårde kapsler 120x1 hårde kapsler 180x1 hårde kapsler 
20x1 hard capsules 60 hard capsules 60x1 hard capsules 120 hard capsules 120x1 hard capsules 180x1 hard capsules
Hvis cytopeni ikke er leukæmirelateret, reducér Imatinib Teva-dosis til 260 mg/m2. 
If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 260 mg/m2.
Ara-C 1.000 mg/m2/12 timer i.v. 
Ara-C 1,000 mg/m2/12 h i.v.
Imatinib Teva kan forårsage, at din krop begynder at ophobe væske (svær væskeretention). 
Imatinib Teva may cause your body to retain water (severe fluid retention).
De mest almindelige rapporterede (≥10%) lægemiddelrelaterede bivirkninger var i begge patientgrupper: let kvalme, opkastning, diarré, abdominalsmerter, træthed, myalgi og muskelkramper samt udslæt. 
The most commonly reported (≥ 10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Der er udført et åbent multicenter fase II-klinisk forsøg (studie B2225) med inklusion af 12 patienter med DFSP, som blev behandlet med Imatinib Teva 800 mg daglig. 
One phase II, open label, multicentre clinical trial (study B2225) was conducted including 12 patients with DFSP treated with imatinib 800 mg daily.
EU/1/12/808/00120 
MARKETING AUTHORISATION NUMBER(S) EU/1/12/808/001-020
BM = Knoglemarv, PB = Perifert blod 
BM = bone marrow, PB = peripheral blood 2 Cytogenetic response criteria:
Jernoxid sort (E172) Propylenglykol 
Iron oxide black (E172) Propylene glycol
Må ikke opbevares ved temperaturer over 30°C. 
SPECIAL STORAGE CONDITIONS Store below 30°C
6-MP (75 mg/m2/dag, p.o.): dag 8-28 
6-MP (75 mg/m2/day, PO): days 8-28
Hvis cytopeni ikke er leukæmirelateret, reducér Imatinib Teva-dosis til 400 mg. 
If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 400 mg.
30 filmovertrukne tabletter 30x1 filmovertrukne tabletter 90 filmovertrukne tabletter 90x1 filmovertrukne tabletter 
30 film-coated tablets 30x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets
(3 timer), dag 1-4; mitoxantron 10 mg/m2 i.v. 
(3 h), days 1-4; Mitoxantrone 10 mg/m2 i.v.
Der er ingen kontrollerede undersøgelser, undtagen hos nyligt diagnosticerede kronisk fase CML-patienter,der har vist klinisk bedring såsom forbedring af sygdomsrelaterede symptomer eller øget overlevelse. 
Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.
Børn med CML i kronisk fase (ved en dosis på 340 mg/m2) 
Paediatric chronic phase CML (at dose 340 mg/m2)
Imatinib var teratogent hos rotter ved administration under organgenese ved doser ≥100 mg/kg, ca. 
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥ 100 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
Kapslerne er ca. 23 mm lange og 9 mm brede. 
The capsules are approximately 23 mm long and 9 mm wide.
Kapslerne er ca. 19 mm lange og 7 mm brede. 
The capsules are approximately 19 mm long and 7 mm wide.
Medianvarigheden af førstevalgsbehandling var henholdsvis 82 og 8 måneder i imatinib- og INFarmene syv år efter, at den sidste patient var rekrutteret. 
Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8 months in the imatinib and IFN arms, respectively.
Delvist 
Partial
9/l og/eller trombocytter < 10 x 109/l 
9/l and/or platelets < 10 x 109/l
- Øvrige indholdsstoffer: calciumhydrogenphosphat, Crospovidon og magnesiumstearat. 
- The other ingredients are calcium hydrogen phosphate, crospovidone and magnesium stearate.
Imatinib Teva monoterapi med 600 mg/dag er sikker og effektiv hos voksne patienter med recidiverende eller refraktiv Ph+ALL, og kan gives indtil der sker sygdomsprogression. 
For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs.
Stoffet hæmmer selektivt proliferationen og inducerer apoptosis i Bcr-Abl-positive cellelinier såvel som i friske leukæmiceller fra Philadelphia-kromosompositiv (Ph+) CML og hos patienter med akut lymfoblastisk leukæmi (ALL). 
The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and ALL patients.
Den anbefalede daglige dosis er 340 mg/m2 til børn med Ph+ALL (den totale dosis må dog ikke overstige 600 mg). 
The dose of 340 mg/m2 daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg).
Tabletterne er ca. 20 mm lange og 10 mm brede. 
The tablets are approximately 20 mm long and 10 mm wide.
Der ses generelt ingen bedring ved indgift af Imatinib Teva til patienter uden genetisk translokation. 
Imatinib administration to patients without the genetic translocation generally results in no improvement.
• Voksne patienter og pædiatriske patienter med nydiagnosticeret Philadelphiakromosom positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. 
• Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
Hos 4% af GIST-patienterne blev undersøgelsesmedicinen seponeret på grund af lægemiddelrelaterede bivirkninger. 
In GIST the study drug was discontinued for drug-related adverse reactions in 4% of patients.
20x1 filmovertrukne tabletter 60 filmovertrukne tabletter 60x1 filmovertrukne tabletter 120 filmovertrukne tabletter 120x1 filmovertrukne tabletter 180x1 filmovertrukne tabletter 
20x1 film-coated tablets 60 film-coated tablets 60x1 film-coated tablets 120 film-coated tablets 120x1 film-coated tablets 180x1 film-coated tablets
Dosering ved MDS/MPD Den anbefalede dosis af Imatinib Teva er 400 mg/dag til voksne patienter med MDS/MPD. 
Posology for MDS/MPD The recommended dose of Imatinib Teva is 400 mg/day for adult patients with MDS/MPD.
Meget almindelige (kan forekomme hos flere end 1 ud af 10 mennesker ) eller almindelige (kan forekomme hos op til 1 ud af 10 mennesker): 
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people):
Hvis cytopeni vedvarer i 4 uger og stadig ikke er leukæmirelateret, seponér Imatinib Teva-behandling indtil ANC ≥ 1,0 x 109/l og trombocytter ≥ 20 x 109/l og genoptag herefter behandlingen med 300 mg. 
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop imatinib until ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l, then resume treatment at 300 mg.
EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF IKKE 
Special precautions for disposal
Ikke almindelige (kan forekomme hos op til 1 ud af 100 mennesker) til sjældne (kan forekomme hos op til 1 ud af 1.000 mennesker): 
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people):
(1 time) dag 4-5; Ara-C 2x 2 g/m2 i.v. 
(1 h) days 4-5; Ara-C 2x 2 g/m2 i.v.
Det skal du vide, før du begynder at tage Imatinib Teva 
What you need to know before you take Imatinib Teva
Hvis cytopeni vedvarer i 4 uger og stadig ikke er leukæmirelateret, seponér Imatinib Teva-behandlingen indtil ANC ≥ 1,0 x 109l og trombocytter ≥ 20 x 109l og genoptag behandling med 200 mg/m2. 
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop Imatinib until ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l, then resume treatment at 200 mg/m2.
Den anbefalede dosis af Imatinib Teva er 600 mg/dag til voksne patienter med Ph+ ALL. 
The recommended dose of Imatinib Teva is 600 mg/day for adult patients with Ph+ ALL.
Der er udført et åbent multicenter, klinisk fase II-studie (studie B2225) med henblik på vurdering af Imatinib Teva i en blandet patientpopulation med livstruende sygdomme forbundet med Abl, Kit eller PDGFR protein-tyrosinkinaser. 
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Kliniske tilfælde af hypotyroidisme er rapporteret hos patienter, der har fået foretaget tyroidektomi, og som er i levothyroxin-erstatningsterapi samtidig med imatinib -behandling (se pkt. 
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib (see section 4.5).
Prægeblækket består af shellac sort jernoxid (E 172) og propylenglycol. 
The printing ink is composed of shellac, iron oxide black (E172) and propylene glycol.
Til doser på 400 mg og derover (se anbefalede doser nedenfor) er en 400 mg filmovertrukken tablet tilgængelig. 
For doses of 400 mg and above (see dose recommendation below) a 400 mg film-coated tablet is available.
I studie I2301 blev der inkluderet i alt 93 børn, unge og yngre voksne (fra 1 til 22 år) med Ph+ALL i et åbent, multicenter, ikke-radomiseret fase III sekventielt kohorte-forsøg. 
In study I2301, a total of 93 paediatric, adolescent and young adult patients (from 1 to 22 years old) with Ph+ ALL were enrolled in an open-label, multicentre, sequential cohort, non-randomized phase III trial, and were treated with imatinib (340 mg/m2/day) in combination with intensive chemotherapy after induction therapy.
• Have kvalme med diarré og opkastning, mavesmerter eller feber (tegn på tarmproblemer). 
• Feeling sick (nausea) with diarrhoea and vomiting, abdominal pain or fever (signs of bowel problems).
2 Cytogenetiske responskriterier: 
Major cytogenetic response2
Til andre doser end 400 mg og 800 mg (se anbefalede doser nedenfor) er en 100 mg hård kapsel tilgængelig. 
For doses other than 400 mg and 800 mg (see dose recommendation below) a 100 mg hard capsule is available.
600 mg som skal tages som én tablet af 400 mg plus 2 tabletter af 100 mg eller som halvanden 400 mg tablet én gang daglig. 
600 mg to be taken as 1 tablet of 400 mg plus 2 tablets of 100 mg or as 1 ½ tablets of 400 mg once a day.
Aktive stoffer der kan øge plasmakoncentrationen af imatinib Stoffer der hæmmer cytochrom P450 isoenzym CYP3A4-aktivitet (f.eks. proteasehæmmere som f.eks. indinavir, lopinavir/ritonavir, ritonavir, saquinavir, teleprevir, nelfinavir, boceprevir; azolantimykotika inklusiv ketoconazol, itraconazol, posaconazol, voriconazol; bestemte makrolider som f.eks. erythromycin, clarithromycin og telithromycin) kan nedsætte metabolismen og øge koncentrationen af imatinib. 
Active substances that may increase imatinib plasma concentrations Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations.
CHR: Undersøgelse 0110 [leukocytter <10 x 109/l, trombocytter <450 x 109/l, myelocyt+metamyelocyt <5% i blodet, ingen blaster eller promyelocytter i blodet, basophiler <20%, ingen ekstramedullær involvering] og i undersøgelse 0102 og 0109 [ANC ≥1,5 x 109/l, trombocytter ≥100 x 109/l, ingen blaster i blodet, BM-blaster <5% og ingen ekstramedullær sygdom] 
CHR: Study 0110 [WBC < 10 x 109/l, platelets < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5% and no extramedullary disease] NEL Same criteria as for CHR but ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l (0102 and 0109 only) RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver (only for 0102 and 0109).